| Literature DB >> 27957388 |
Jieyu He1, Jun Zhao2,3, Wenbo Zhu1, Daxun Qi2, Lina Wang1, Jinfang Sun1, Bei Wang1, Xu Ma2,3, Qiaoyun Dai2, Xiaojin Yu1.
Abstract
MicroRNAs (miRNAs) may promote the development and progression of human cancers. Therefore, components of the miRNA biogenesis pathway may play critical roles in human cancer. Single nucleotide polymorphisms (SNPs) or mutations in genes involved in the miRNA biogenesis pathway may alter levels of gene expression, affecting disease susceptibility. Results of previous studies on genetic variants in the miRNA biogenesis pathway and cancer risk were inconsistent. Therefore, a meta-analysis is needed to assess the associations of these genetic variants with human cancer risk. We searched for relevant articles from PubMed, Web of Science, CNKI, and CBM through Jun 21, 2016. In total, 21 case-control articles met all of the inclusion criteria for the study. Significant associations were observed between cancer risk and the DGCR8polymorphism rs417309 G >A (OR 1.22, 95% CI [1.04-1.42]), as well as the DICER1 polymorphism rs1057035 TT (OR 1.13, 95% CI [1.05-1.22]). These SNPs exhibit high potential as novel diagnostic markers. Future studies with larger sample sizes and more refined analyses are needed to shed more light on these findings.Entities:
Keywords: Cancer risk; Meta-analysis; MicroRNA biogenesis
Year: 2016 PMID: 27957388 PMCID: PMC5147022 DOI: 10.7717/peerj.2706
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1MiRNA biogenesis pathway.
Figure 2Flow diagram of the study selection process.
Characteristics of the studies eligible for meta-analysis.
| Author | Year | Cancer type | Country | Ethnicity | Controls | Case | Control | Method | Polymorphism site | nos |
|---|---|---|---|---|---|---|---|---|---|---|
| 2008 | renal cell carcinoma | American | Caucasian | PB | 279 | 278 | SNPlex |
| 8 | |
| 2008 | bladder cancer | American | Caucasian | HB | 746 | 746 | SNPlex |
| 7 | |
| 2008 | esophageal cancer | American | Caucasian | HB | 346 | 346 | SNPlex |
| 7 | |
| 2010 | lung cancer | Korea | Asian | HB | 100 | 100 |
| 7 | ||
| 2011 | breast cancer | Korea | Asian | HB | 559 | 567 | TaqMan |
| 7 | |
| 2012 | head and neck cancer | China | Asian | HB | 397 | 900 | TaqMan |
| 7 | |
| 2013 | cervical carcinoma | China | Asian | HB | 1486 | 1549 | TaqMan |
| 7 | |
| 2013 | breast cancer | China | Asian | HB | 878 | 900 | TaqMan |
| 7 | |
| 2013 | hepatocellular carcinoma | China | Asian | HB | 1300 | 2688 | TaqMan |
| 7 | |
| 2013 | colorectal cancer | Czech | Caucasian | HB | 197 | 202 | TLDA |
| 7 | |
| 2013 | bladder cancer | China | Asian | HB | 685 | 730 | TaqMan |
| 7 | |
| 2014 | oral cancer | India | Asian | HB | 451 | 452 | Taqman |
| 7 | |
| 2015 | Colorectal Cancer | Korean | Asian | HB | 408 | 400 | PCR-RFLP |
| 7 | |
| 2015 | Lymphocytic Leukemia | Spanish | Caucasian | HB | 123 | 391 | Taqman |
| 7 | |
| 2015 | gastric cancer | China | Asian | HB | 137 | 142 |
| 7 | ||
| 2015 | colorectal cancer | China | Asian | HB | 163 | 142 |
| 7 | ||
| 2013 | lung cancer | China | Asian | HB | 600 | 600 | TaqMan |
| 7 | |
| 2013 | esophageal cancer | China | Asian | HB | 380 | 380 |
| 7 | ||
| 2012 | gastric cancer | China | Asian | HB | 1674 | 1852 | TaqMan |
| 7 | |
| 2015 | esophageal cancer | Europe | Caucasian | HB | 600 | 600 | TaqMan |
| 7 | |
| 2014 | Lymphocytic Leukemia | Spanish | Caucasian | HB | 213 | 387 |
| 7 |
Analysis of associations between SNPs from DROSHA, DGCR8, XPO5, RAN, and DICER1 and cancer risk.
| Gene(locus) | Position | studies | Method | Cases /controls | WW vs.WM+MM | WW vs. WM+MM | WW vs.WM+MM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | OR | OR | |||||||||||
|
| 3′UTR | 5 | R | 1982/2293 | 0.91(0.75,1.10) | 0.209 | 36.2 | 1.34(0.78,2.30) | 0.070 | 69.6 | 1.05(0.83,1.33) | 0.026 | 63.9 |
|
| 3′UTR | 7 | F | 3327/3658 | 1.04(0.78,1.39) | 0.147 | 47.8 | ||||||
|
| 3′UTR | 7 | R | 2610/3046 | 1.07(0.90,1.28) | 0.571 | 0.0 | 1.22(0.85,1.75) | 0.017 | 70.7 | 1.20(0.94,1.54) | 0.038 | 46.1 |
|
| 3′UTR | 7 | F | 8065/5478 | 0.83(0.66,1.03) | 0.652 | 0.0 | 0.95(0.88,1.03) | 0.260 | 25.7 | 0.94(0.87,1.01) | 0.463 | 0.0 |
|
| 3′UTR | 9 | R | 7702/5335 | 1.40(0.72,2.69) | 0.001 | 92.6 | 0.99(0.73,1.33) | 0.002 | 79.2 | 1.17(0.87,1.57) | 0.000 | 88.7 |
|
| 3′UTR | 5 | F | 5642/6489 | 0.98(0.87,1.11) | 0.494 | 0.0 | – | – | – | – | – | – |
|
| 3′UTR | 10 | F | 7783/8925 | 1.21(0.90,1.62) | 0.182 | 44.0 | ||||||
|
| 3′UTR | 9 | R | 3222/3240 | 1.02(0.89,1.18) | 0.000 | 79.6 | 0.90(0.73,1.10) | 0.396 | 0.0 | 0.98(0.87,1.10) | 0.001 | 70.9 |
|
| 3′UTR | 7 | F | 3102/3419 | 1.01(0.81,1.26) | 0.889 | 0.0 | 1.13(0.97,1.32) | 0.116 | 49.3 | 1.09(0.96,1.24) | 0.339 | 11.8 |
Notes.
W: major allele M: minor allele.
Asian population.
Caucasian population.
All over.
WM+MM vs. WW.
Method: F, Fixed model; R, Random model.
Figure 3Forest plot for the relationship between the microRNA biogenesis pathway genes polymorphism and cancer risk.
Figure 4Funnel plot for publication bias test. OR, odds ratio; SE, standard error.
Results of Egger’s and Begg’s tests for publication bias.
| Category | Studies | Begg’s test | Egger’s test | ||
|---|---|---|---|---|---|
| (95%) CI | |||||
|
| 5 | 1.47 | 0.14 | (−0.87,7.07) | 0.09 |
|
| 7 | 1.20 | 0.23 | (−4.79,0.79) | 0.13 |
|
| 7 | 1.20 | 0.23 | (−2.39,5.13) | 0.39 |
|
| 7 | 0.3 | 0.76 | (−0.20,0.12) | 0.53 |
|
| 9 | 1.15 | 0.25 | (−2.66,5.07) | 0.49 |
|
| 5 | −1.32 | 0.19 | (−3.75,1.80) | 0.39 |
|
| 10 | 0.72 | 0.47 | (−2.11,4.20) | 0.76 |
|
| 9 | 0.10 | 0.92 | (−2.98,8.01) | 0.32 |
|
| 7 | −1.05 | 0.293 | (−3.81,2,91) | 0.77 |